Drug
Tisotumab vedotin clinical trials
Also written TIVDAK.
Keep track of what changes. Save the tisotumab vedotin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Seagen Inc. (5) · Seagen, a wholly owned subsidiary of Pfizer (1) · Zai Lab (Shanghai) Co., Ltd. (1) · Genmab (1) · GOG Foundation (1) · Pfizer (1)
Studies
Open first, then newest update. How each study uses tisotumab vedotin is read from its arms, and is right about nine times in ten.
Testing it · 10
- Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerRecruitingPhase 4PfizerNCT06952660Written as TIVDAK
- Tisotumab Vedotin in Squamous Cell Carcinoma of the VulvaNot yet recruitingPhase 2GOG FoundationNCT07672782Written as Tisotumab Vedotin
- Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical CancerCompletedPhase 3Seagen, a wholly owned subsidiary of PfizerNCT04697628Written as tisotumab vedotin
- To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid MalignanciesCompletedPhase 1Zai Lab (Shanghai) Co., Ltd.NCT05866354Written as Tisotumab Vedotin
- A Trial of Tisotumab Vedotin in Cervical CancerCompletedPhase 2Seagen Inc.NCT03438396Written as tisotumab vedotin
- A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)CompletedPhase 2Seagen Inc.NCT03657043Written as tisotumab vedotin
- A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid MalignanciesCompletedPhase 1/2GenmabNCT03913741Written as tisotumab vedotin
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedPhase 1/2Seagen Inc.NCT02001623Written as Tisotumab Vedotin (HuMax-TF-ADC)
- Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedPhase 2Seagen Inc.NCT03245736Written as Tisotumab Vedotin
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedPhase 1/2Seagen Inc.NCT02552121Written as Tisotumab vedotin (HuMax-TF-ADC)
Given in every arm · 2 — tisotumab vedotin is usual care beside what is tested
- Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsActive, not recruitingPhase 2Seagen, a wholly owned subsidiary of PfizerNCT03485209Written as tisotumab vedotin
- Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerTerminatedPhase 1/2Seagen, a wholly owned subsidiary of PfizerNCT03786081Written as Tisotumab Vedotin
As the comparator · 1 — what is tested is compared with tisotumab vedotin
Codes
What other systems call tisotumab vedotin · ClinicalTrials.gg INT001329
- MeSH (NLM) C000707142tisotumab vedotinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) T41737F88ATISOTUMAB VEDOTINConfirmed FDA, NLM, Wikidata
- RxNorm 2571094One source FDA
- Wikidata Q108670929tisotumab vedotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C113164Tisotumab VedotinOne source FDA
- DrugBank DB16732One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707142 | tisotumab vedotin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | T41737F88A | TISOTUMAB VEDOTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2571094 | — | One source FDA |
| Wikidata | Q108670929 | tisotumab vedotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113164 | Tisotumab Vedotin | One source FDA |
| DrugBank | DB16732 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.